Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)

Brain Tumor Clinical Trial

— PRURI-C  

Official title:

Study on the Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03673878
• Other study ID #: 29BRC18.0155
• Status: Completed
• Start date: June 29, 2020
• Est. completion date: September 5, 2021

Study information

• Verified date: January 2022
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The association between the presence of pruritus, especially centrofacial, and the presence of a brain tumor is a widespread notion in the medical community but based on a single publication by Andreev et al. in the British Journal of Dermatology published in 1975. No other study has studied this association with a rigorous methodology. The aim of this study is to evaluate the prevalence of pruritus in patients with one or more primary or secondary brain tumor(s), benign(s) or malignant(s).

Description:

• Monocentric prospective observational study

• On the inclusion period

• Patients who are seen in radiotherapy consultation and / or department of neurosurgery

• Complying with the inclusion criteria, not falling within the exclusion criteria

• Re-reading of cerebral MRI (cMRI) with precision on the location(s) of the brain tumor(s) according to a predefined anatomic descriptive diagram

• Complete the questionnaire by a dermatologist (characteristics of pruritus, brain lesion(s), characteristics of the population)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: September 5, 2021
• Est. primary completion date: September 5, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Age > 18 years

• Diagnosis of benign or malignant brain tumor, primary or secondary.

• Accepted non-opposition

• Realization of a cerebral MRI (cMRI)

Exclusion criteria:

• Age < 18 years

• Absence of cerebral imaging of the cMRI type

• Absence of non opposition

• Realization of a treatment modifying the brain structure (radiotherapy / surgery)

Related Conditions & MeSH terms

• Brain Neoplasms
• Brain Tumor
• Pruritus

Locations

Country	Name	City	State
France	Service de dermatologie, CHRU BREST	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of itching for more than 1 week in a patient with one or more brain tumor(s), primary or secondary, benign(s) or malignant(s).	Presence of itching for more than 1 week in a patient with one or more brain tumor(s), primary or secondary, benign(s) or malignant(s).	1 year